Cardiovascular Disease Risk in Calcium Pyrophosphate Deposition Disease: A Nationwide Study of Veterans

被引:12
|
作者
Bashir, Maaman [1 ]
Sherman, Katherine A. [2 ]
Solomon, Daniel H. [3 ]
Rosenthal, Ann [1 ,2 ]
Tedeschi, Sara K. [3 ]
机构
[1] Med Coll Wisconsin, Milwaukee, WI 53226 USA
[2] Zablocki VA Med Ctr, Milwaukee, WI USA
[3] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA
关键词
RHEUMATOID-ARTHRITIS; ARTERY CALCIFICATION; GOUT; ASSOCIATION; MORTALITY; CHONDROCALCINOSIS; EVENTS;
D O I
10.1002/acr.24783
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective Calcium pyrophosphate deposition (CPPD) disease represents a common crystalline arthritis with a range of manifestations. Our goal was to investigate risks for cardiovascular events in patients with CPPD. Methods We performed a retrospective matched cohort analysis in the Veterans Health Administration Corporate Data Warehouse, 2010-2014. CPPD was defined by >= 1 International Classification of Diseases, Ninth Revision codes for chondrocalcinosis or calcium metabolism disorder. CPPD patients were age- and sex-matched to approximately 4 patients without codes for CPPD; we excluded patients with a cardiovascular event during the 365 days prior to the index date. Demographic information, traditional cardiovascular risk factors, medications, and health care utilization were assessed at baseline. The primary outcome was a major adverse cardiovascular event (MACE: myocardial infarction, acute coronary syndrome, coronary revascularization, stroke, or death). Secondary outcomes included individual components of MACE. Cox proportional hazards models estimated fully adjusted hazard ratios (HRs) and 95% confidence intervals (95% CIs). Results We identified 23,124 CPPD patients matched to 86,629 non-CPPD patients with >250,000 person-years of follow-up. The study population was 96% male, mean age was 78 years, and 75% were White. The frequency of traditional cardiovascular risk factors was similar between the 2 cohorts. CPPD was not significantly associated with risk for MACE (HR 0.98 [95% CI 0.94-1.02]) in fully adjusted models, though risks of myocardial infarction, acute coronary syndrome, and stroke were significantly higher in the CPPD cohort compared to the non-CPPD cohort. Conclusion CPPD did not confer an increased risk for MACE, a composite end point including all-cause mortality. Our results propose CPPD as a novel risk factor for MACE components, including myocardial infarction, acute coronary syndrome, and stroke.
引用
收藏
页码:277 / 282
页数:6
相关论文
共 50 条
  • [21] Calcium pyrophosphate dihydrate crystal deposition disease
    Ince, A
    Sundaram, M
    ORTHOPEDICS, 1996, 19 (01) : 77 - &
  • [23] Calcium pyrophosphate deposition disease: clinical manifestations
    Ferrone, C.
    Andracco, R.
    Cimmino, M. A.
    REUMATISMO, 2011, 63 (04) : 246 - 252
  • [24] DISEASES ASSOCIATED WITH CALCIUM PYROPHOSPHATE DEPOSITION DISEASE
    JONES, AC
    CHUCK, AJ
    ARIE, EA
    GREEN, DJ
    DOHERTY, M
    SEMINARS IN ARTHRITIS AND RHEUMATISM, 1992, 22 (03) : 188 - 202
  • [25] The Role of ANK in Calcium Pyrophosphate Deposition Disease
    Elizabeth Mitton-Fitzgerald
    Claudia M. Gohr
    Brittany Bettendorf
    Ann K. Rosenthal
    Current Rheumatology Reports, 2016, 18
  • [26] Imaging and management of calcium pyrophosphate deposition disease
    Issa, Wasim
    Mercer, Ronald
    Yinh, Janeth
    Guermazi, Ali
    Jarraya, Mohamed
    SKELETAL RADIOLOGY, 2025,
  • [27] Calcium pyrophosphate deposition disease induced sacroiliitis
    Martens, Henk A.
    van Bokhoven, Steven C.
    Stenger, Annemiek A. M. E.
    RHEUMATOLOGY, 2018, 57 (08) : 1422 - 1422
  • [28] Calcium pyrophosphate deposition disease moves into the spotlight
    Dalbeth, Nicola
    Tedeschi, Sara K.
    LANCET RHEUMATOLOGY, 2023, 5 (09): : E497 - E499
  • [29] Suppressive treatment of calcium pyrophosphate deposition disease
    Rothschild, Bruce
    ARTHRITIS AND RHEUMATISM, 2007, 56 (09): : 3172 - 3172
  • [30] Sacroiliitis due to calcium pyrophosphate deposition disease
    Moreno Martinez, Maria Jose
    Moreno Ramos, Manuel J.
    Linares Ferrando, Luis F.
    REUMATOLOGIA CLINICA, 2018, 14 (03): : 175 - 176